Madorra Revenue and Competitors
Estimated Revenue & Valuation
- Madorra's estimated annual revenue is currently $1.6M per year.
- Madorra's estimated revenue per employee is $84,000
Employee Data
- Madorra has 19 Employees.
- Madorra grew their employee count by 6% last year.
Madorra's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Co-Founder | Reveal Email/Phone |
2 | CEO and Co-Founder | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
Madorra Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 45 | -6% | N/A | N/A |
#2 | $14.6M | 0 | N/A | $4.2M | N/A |
#3 | $4M | 36 | -28% | N/A | N/A |
#4 | $18.3M | 131 | N/A | N/A | N/A |
#5 | $3.9M | 35 | N/A | N/A | N/A |
#6 | $21.9M | 142 | 9% | N/A | N/A |
#7 | $5.2M | 46 | 7% | N/A | N/A |
#8 | $0.8M | 10 | 11% | N/A | N/A |
#9 | $4M | 38 | -17% | $33.8M | N/A |
#10 | $4.9M | 46 | -25% | $29.2M | N/A |
What Is Madorra?
Madorra is empowering women to live fuller, richer, healthier lives. Our first product is changing the paradigm for treating vaginal dryness by providing a medical device solution to a problem that has previously only been served by pharmaceuticals. We're giving postmenopausal women and breast cancer survivors the power to choose the non-hormonal treatment option they want. Madorra has developed the first, non-invasive, non-hormonal medical device to treat vaginal atrophy. This is an easy-to-use, at-home device, providing both immediate and long-term benefits.
keywords:N/A
N/A
Total Funding
19
Number of Employees
$1.6M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Madorra News
... Madorra Inc., which is developing a non-pharmaceutical solution for vaginal dryness for breast cancer survivors and postmenopausal women...
Other Companies in Portland
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.6M | 19 | -17% | $44M |
#2 | $3.1M | 19 | N/A | N/A |
#3 | $1.1M | 19 | -76% | $8.2M |
#4 | $4.6M | 19 | 6% | N/A |
#5 | $2.4M | 19 | -10% | N/A |